Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Graefen

Showing results (631-640 of 850) with videos related to

Pageof 85
Sort By:
Pathology Oncology Research : POR|April 7, 2018
A Multi-Institutional Validation of Gleason Score Derived from Tissue Microarray CoresSami-Ramzi Leyh-Bannurah, Dominique Trudel, Mathieu Latour, et al.
Scientific Reports|May 23, 2024
Synthesis and new DNA targeting activity of 6- and 7-tert-butylfascaplysinsSergey A Dyshlovoy, Wael Y Mansour, Natalia A Ramm, et al.
Oncology Letters|October 19, 2018
High concordance of TMPRSS-ERG fusion between primary prostate cancer and its lymph node metastasesFranziska Brandi, Katharina Grupp, Claudia Hube-Magg, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|July 23, 2016
p16 upregulation is linked to poor prognosis in ERG negative prostate cancerChristoph Burdelski, Tatsiana Dieckmann, Asmus Heumann, et al.
European Urology|September 11, 2012
Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysisAlberto Briganti, Martin Spahn, Steven Joniau, et al.
European Urology|February 4, 2014
Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional studySteven Joniau, Alberto Briganti, Paolo Gontero, et al.
The Journal of Pathology|June 25, 2013
Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancersAntje Krohn, Annemarie Seidel, Lia Burkhardt, et al.
Marine Drugs|December 4, 2020
Efficacy and Mechanism of Action of Marine Alkaloid 3,10-Dibromofascaplysin in Drug-Resistant Prostate Cancer CellsSergey A Dyshlovoy, Moritz Kaune, Jessica Hauschild, et al.
The Prostate|January 15, 2016
Cytoplasmic accumulation of ELAVL1 is an independent predictor of biochemical recurrence associated with genomic instability in prostate cancerNathaniel Melling, Berivan Taskin, Claudia Hube-Magg, et al.
Plos One|August 1, 2015
High-Level HOOK3 Expression Is an Independent Predictor of Poor Prognosis Associated with Genomic Instability in Prostate CancerNathaniel Melling, Levon Harutyunyan, Claudia Hube-Magg, et al.
Pageof 85

Showing results (631-640 of 850) with videos related to

Sort By:
Pageof 85
Pathology Oncology Research : POR|April 7, 2018
A Multi-Institutional Validation of Gleason Score Derived from Tissue Microarray CoresSami-Ramzi Leyh-Bannurah, Dominique Trudel, Mathieu Latour, et al.
Scientific Reports|May 23, 2024
Synthesis and new DNA targeting activity of 6- and 7-tert-butylfascaplysinsSergey A Dyshlovoy, Wael Y Mansour, Natalia A Ramm, et al.
Oncology Letters|October 19, 2018
High concordance of TMPRSS-ERG fusion between primary prostate cancer and its lymph node metastasesFranziska Brandi, Katharina Grupp, Claudia Hube-Magg, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|July 23, 2016
p16 upregulation is linked to poor prognosis in ERG negative prostate cancerChristoph Burdelski, Tatsiana Dieckmann, Asmus Heumann, et al.
European Urology|September 11, 2012
Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysisAlberto Briganti, Martin Spahn, Steven Joniau, et al.
European Urology|February 4, 2014
Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional studySteven Joniau, Alberto Briganti, Paolo Gontero, et al.
The Journal of Pathology|June 25, 2013
Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancersAntje Krohn, Annemarie Seidel, Lia Burkhardt, et al.
Marine Drugs|December 4, 2020
Efficacy and Mechanism of Action of Marine Alkaloid 3,10-Dibromofascaplysin in Drug-Resistant Prostate Cancer CellsSergey A Dyshlovoy, Moritz Kaune, Jessica Hauschild, et al.
The Prostate|January 15, 2016
Cytoplasmic accumulation of ELAVL1 is an independent predictor of biochemical recurrence associated with genomic instability in prostate cancerNathaniel Melling, Berivan Taskin, Claudia Hube-Magg, et al.
Plos One|August 1, 2015
High-Level HOOK3 Expression Is an Independent Predictor of Poor Prognosis Associated with Genomic Instability in Prostate CancerNathaniel Melling, Levon Harutyunyan, Claudia Hube-Magg, et al.
Pageof 85